Yahoo Finance·2026-01-13 15:35Core Insights - Eli Lilly and Novo Nordisk are leading companies in the weight loss drug market, which is projected to reach nearly $100 billion by 2030 [1][2] - Both companies produce GLP-1 drugs that have gained significant popularity, with demand often exceeding supply [2] Novo Nordisk - Novo Nordisk has a first-to-market advantage with both injectable and now oral weight loss drugs, having launched Ozempic in early 2018 and Wegovy in 2021 [4][5] - The obesity care segment has driven revenue growth of 37%, reaching 59.9 billion Danish kroner (approximately $9 billion) in the first nine months of 2025 [5] Eli Lilly - Eli Lilly received approval for its tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, in 2022 and 2023 respectively [6] - The company has experienced significant revenue growth, with Mounjaro and Zepbound generating about $10 billion in revenue in a recent quarter, contributing to an overall sales increase of 54% [8]